Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Eyepoint Pharmaceuticals Inc (EYPT)

Eyepoint Pharmaceuticals Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 453,131
  • Shares Outstanding, K 52,084
  • Annual Sales, $ 46,020 K
  • Annual Income, $ -70,800 K
  • 60-Month Beta 1.59
  • Price/Sales 9.90
  • Price/Cash Flow N/A
  • Price/Book 1.82
Trade EYPT with:

Options Overview Details

View History
  • Implied Volatility 81.51% ( -7.33%)
  • Historical Volatility 56.70%
  • IV Percentile 8%
  • IV Rank 9.56%
  • IV High 406.22% on 11/15/23
  • IV Low 47.18% on 06/20/24
  • Put/Call Vol Ratio 12.90
  • Today's Volume 431
  • Volume Avg (30-Day) 317
  • Put/Call OI Ratio 2.67
  • Today's Open Interest 38,577
  • Open Int (30-Day) 42,402

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.55
  • Number of Estimates 4
  • High Estimate -0.48
  • Low Estimate -0.65
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +9.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.95 +3.21%
on 06/21/24
10.94 -25.00%
on 06/03/24
-2.51 (-23.39%)
since 05/31/24
3-Month
7.95 +3.21%
on 06/21/24
23.65 -65.30%
on 04/12/24
-12.07 (-59.52%)
since 04/01/24
52-Week
5.67 +44.71%
on 10/30/23
30.99 -73.52%
on 02/08/24
-0.49 (-5.69%)
since 06/30/23

Most Recent Stories

More News
Stocks Settle Higher on Solid Earnings and Fed Rate Cut Optimism

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +1.03%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.13%. US stock indexes...

$SPX : 5,472.35 (+0.22%)
SPY : 545.08 (+0.16%)
$DOWI : 39,204.80 (+0.22%)
DIA : 392.03 (+0.23%)
$IUXX : 19,774.07 (+0.46%)
QQQ : 481.15 (+0.43%)
ZNU24 : 109-055 (-0.74%)
SMCI : 811.44 (-0.97%)
NVDA : 124.14 (+0.49%)
AMD : 156.77 (-3.35%)
KLAC : 823.94 (-0.07%)
AVGO : 1,646.16 (+2.53%)
Stocks Climb on Strength in Chips Stocks and Fed Rate Cut Optimism

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.61%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.60%. US stock indexes this morning...

$SPX : 5,472.35 (+0.22%)
SPY : 545.08 (+0.16%)
$DOWI : 39,204.80 (+0.22%)
DIA : 392.03 (+0.23%)
$IUXX : 19,774.07 (+0.46%)
QQQ : 481.15 (+0.43%)
ZNU24 : 109-055 (-0.74%)
MU : 131.14 (-0.30%)
NVDA : 124.14 (+0.49%)
AMD : 156.77 (-3.35%)
GFS : 49.69 (-1.72%)
KLAC : 823.94 (-0.07%)
Stocks Push Higher on Fed Rate Cut Optimism

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.54%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.51%. US stock indexes this morning...

$SPX : 5,472.35 (+0.22%)
SPY : 545.08 (+0.16%)
$DOWI : 39,204.80 (+0.22%)
DIA : 392.03 (+0.23%)
$IUXX : 19,774.07 (+0.46%)
QQQ : 481.15 (+0.43%)
ZNU24 : 109-055 (-0.74%)
PARA : 10.09 (-2.89%)
MU : 131.14 (-0.30%)
IR : 89.57 (-1.40%)
FRPT : 129.07 (-0.25%)
PRFT : 74.79 (+0.01%)
Why Shares of EyePoint Pharmaceuticals Were Rising Monday

The company reported positive trial data for its lead therapy to treat two different eye conditions.

AMD : 156.77 (-3.35%)
EYPT : 8.21 (-5.63%)
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END

OKYO : 1.1900 (unch)
OKYO.LN : 1.400 (-24.32%)
NVS : 106.60 (+0.13%)
ALDX : 3.31 (unch)
OCUL : 6.84 (-0.37%)
EYPT : 8.21 (-5.63%)
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments

/PRNewswire/ -- The Global Dry Eye Syndrome market is witnessing continued growth due to the factors such as the growing demand for effective treatments, the...

OKYO : 1.1900 (unch)
NVS : 106.60 (+0.13%)
ALDX : 3.31 (unch)
OCUL : 6.84 (-0.37%)
EYPT : 8.21 (-5.63%)
S&P Futures Muted as Mixed Earnings Weigh on Sentiment, PMI Data in Focus

June S&P 500 futures (ESM23) are trending up +0.07% this morning after three major U.S. benchmark indices finished the regular session in the red as investors assessed a mixed slate of corporate earnings...

ESM23 : 4,453.35s (+0.61%)
TSLA : 209.85 (+6.05%)
T : 18.89 (-1.15%)
AXP : 233.62 (+0.89%)
LRCX : 1,055.82 (-0.85%)
PG : 163.35 (-0.95%)
HCA : 316.88 (-1.37%)
SLB : 46.67 (-1.08%)
RIO.L.EB : 5,234.000 (+0.48%)
EL.P.DX : 201.800 (+0.60%)
WISH : 5.13 (-0.97%)
CSX : 33.51 (+0.18%)
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy

EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation (NASDAQ: RLYB),...

RLYB : 1.3850 (+3.36%)
EYPT : 8.21 (-5.63%)
EYEPOINT SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against EyePoint Pharmaceuticals ("Eyepoint" or...

EYPT : 8.21 (-5.63%)
EYEPOINT SHAREHOLDER ACTION REMINDER

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against EyePoint Pharmaceuticals ("Eyepoint" or...

EYPT : 8.21 (-5.63%)

Business Summary

EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known...

See More

Key Turning Points

3rd Resistance Point 9.79
2nd Resistance Point 9.51
1st Resistance Point 9.11
Last Price 8.21
1st Support Level 8.43
2nd Support Level 8.15
3rd Support Level 7.75

See More

52-Week High 30.99
Fibonacci 61.8% 21.32
Fibonacci 50% 18.33
Fibonacci 38.2% 15.34
Last Price 8.21
52-Week Low 5.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar